Abstract
Background: A progressive delay in the age of first conception results in an increased frequency of endometrial cancer patients in reproductive age and desiring childbearing. Case: A 38-year-old infertile woman with stage I endometrioid adenocarcinoma was treated with gonadotropin releasing hormone agonist (GnRHa) and levonorgestrel-releasing intrauterine device (LNG-IUD). After disease remission, she underwent a controlled ovarian stimulation for standard in vitro fertilization (IVF) program and had a pregnancy delivering a healthy male baby. Total laparoscopic hysterectomy with bilateral salpingo-oophorectomy was performed four months after delivery. The patient is free of disease after 3-year follow-up. Conclusion: GnRHa plus LNG-IUD followed by IVF program is a safe and effective fertility-sparing strategy to manage infertile patients with stage I endometrial cancer.
| Original language | English |
|---|---|
| Pages (from-to) | 219-221 |
| Number of pages | 3 |
| Journal | Gynecological Endocrinology |
| Volume | 29 |
| Issue number | 3 |
| DOIs | |
| Publication status | Published - Mar 2013 |
Fingerprint
Keywords
- Endometrial cancer
- Fertility
- GnRH-a
- IVF
- LNG-IUD
ASJC Scopus subject areas
- Endocrinology
- Endocrinology, Diabetes and Metabolism
- Obstetrics and Gynaecology
Cite this
Gonadotropin releasing hormone agonist and levonorgestrel-intrauterine device followed by in vitro fertilization program as management strategy for an infertile endometrial cancer patient : A case report. / Nucera, Giuseppe; Mandato, Vincenzo Dario; Gelli, Maria Carolina; Palomba, Stefano; La Sala, Giovanni Battista.
In: Gynecological Endocrinology, Vol. 29, No. 3, 03.2013, p. 219-221.Research output: Contribution to journal › Article
}
TY - JOUR
T1 - Gonadotropin releasing hormone agonist and levonorgestrel-intrauterine device followed by in vitro fertilization program as management strategy for an infertile endometrial cancer patient
T2 - A case report
AU - Nucera, Giuseppe
AU - Mandato, Vincenzo Dario
AU - Gelli, Maria Carolina
AU - Palomba, Stefano
AU - La Sala, Giovanni Battista
PY - 2013/3
Y1 - 2013/3
N2 - Background: A progressive delay in the age of first conception results in an increased frequency of endometrial cancer patients in reproductive age and desiring childbearing. Case: A 38-year-old infertile woman with stage I endometrioid adenocarcinoma was treated with gonadotropin releasing hormone agonist (GnRHa) and levonorgestrel-releasing intrauterine device (LNG-IUD). After disease remission, she underwent a controlled ovarian stimulation for standard in vitro fertilization (IVF) program and had a pregnancy delivering a healthy male baby. Total laparoscopic hysterectomy with bilateral salpingo-oophorectomy was performed four months after delivery. The patient is free of disease after 3-year follow-up. Conclusion: GnRHa plus LNG-IUD followed by IVF program is a safe and effective fertility-sparing strategy to manage infertile patients with stage I endometrial cancer.
AB - Background: A progressive delay in the age of first conception results in an increased frequency of endometrial cancer patients in reproductive age and desiring childbearing. Case: A 38-year-old infertile woman with stage I endometrioid adenocarcinoma was treated with gonadotropin releasing hormone agonist (GnRHa) and levonorgestrel-releasing intrauterine device (LNG-IUD). After disease remission, she underwent a controlled ovarian stimulation for standard in vitro fertilization (IVF) program and had a pregnancy delivering a healthy male baby. Total laparoscopic hysterectomy with bilateral salpingo-oophorectomy was performed four months after delivery. The patient is free of disease after 3-year follow-up. Conclusion: GnRHa plus LNG-IUD followed by IVF program is a safe and effective fertility-sparing strategy to manage infertile patients with stage I endometrial cancer.
KW - Endometrial cancer
KW - Fertility
KW - GnRH-a
KW - IVF
KW - LNG-IUD
UR - http://www.scopus.com/inward/record.url?scp=84874293475&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=84874293475&partnerID=8YFLogxK
U2 - 10.3109/09513590.2012.738726
DO - 10.3109/09513590.2012.738726
M3 - Article
C2 - 23153053
AN - SCOPUS:84874293475
VL - 29
SP - 219
EP - 221
JO - Gynecological Endocrinology
JF - Gynecological Endocrinology
SN - 0951-3590
IS - 3
ER -